CTLT Catalent
- 56.370
- -0.160-0.28%
Catalent News
Siren Biotechnology And Catalent Partner To Manufacture AAV Gene Therapies For Cancer
Siren Biotechnology And Catalent Partner To Manufacture AAV Gene Therapies For Cancer
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments
Health Care Climbs as Amgen Surges on Obesity-Drug Plans - Health Care Roundup
Health-care companies rose after a surprising new entrant in the obesity-drug bonanza from one biotech giant. Amgen shares surged after the biotech giant said it saw encouraging signs from its inject
Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
Wall Street's major indexes all jumped on the heels of a softer-than-expected jobs report released Friday by the US Department of Labor. In company news, Apple (AAPL) reported fiscal Q2 diluted earnin
Catalent, Novo Nordisk Receive FTC Request for More Information
UPDATE 1-US FTC Seeks More Information on Novo Nordisk Parent-Catalent Deal
How Novo-Catalent Deal Affects Halozyme (HALO)?
Here's How Novo Holdings' Catalent (CTLT) Acquisition Affects Laughing Water Capital
Novo Nordisk's Wegovy Sales More Than Doubled. Why the Stock Is Falling. -- Barrons.com
By Callum Keown Novo Nordisk hiked its full-year guidance Thursday as sales of its weight-loss drug Wegovy more than doubled in the first three months of 2024. The Danish pharmaceutical giant, which
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Novo Nordisk A/S (NYSE:NVO) is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase comes despite supply constraints and competition from El
Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock's Falling.
The Danish pharmaceutical giant, which became Europe's most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
Catalent Inc Earnings Missed, Revenue Was in Line With Estimates
Unusual Options Activity: STE, VST and Others Attract Market Bets, STE V/OI Ratio Reaches 107.7
EST Apr 29th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
Goldman's Debt Issuers Stocks Basket
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48.
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Top 10 Best Performing S&P 500 Health Care Stocks of 2024
Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal
Novo Nordisk (NOVO-B.CO) parent Novo Nordisk Foundation filed a new application to secure the US Federal Trade Commission's approval on its proposed acquisition of manufacturing subcontractor Catalent
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down about 0.2% The iShares Biotechnology ETF (IBB) rose 0.
Analysis
Price Target
No Data
